Five years from the start of the COVID-19 pandemic, numerous academic studies have shown how the novel coronavirus affects ocular health.

In today’s digitally driven world, the average person spends a significant portion of their day looking at screens—phones, ...

The FDA issued a complete response letter for the resubmission of the reproxalap new drug application for the treatment of ...

The Company expects to have topline data from 2 trials assessing the effect of reproxalap on dry eye disease symptoms available in the second quarter of 2025.

The U.S. Food and Drug Administration has once again declined to approve Aldeyra Therapeutics treatment for dry eye disease, ...

The topical ocular drug is an investigational new drug candidate that requires more well-controlled studies to establish ...

Aldeyra Therapeutics has planned to announce top-line results from ongoing field and chamber clinical trials in the second ...

The FDA has set back Aldeyra Therapeutics’ ambitions to win approval for its dry eye disease, rejecting its second ...

Analysis - In an era where screens dominate our daily lives, a silent epidemic is sweeping the globe. Digital eye strain, a ...

Background To investigate whether certain dry eye (DE) metrics relate to oral and pain manifestations of Sjögren’s disease ...

Urcosimod stable in single-use ampoules for more than 2½ years FDA requires drug to show long-term shelf stability for ...

If you have dry, itchy, or bloodshot eyes, it could be that you are producing fewer tears because you're not sleeping enough.